Armodafinil to reduce the sleepiness related side‐effects of sleep restriction therapy being used to treat insomnia disorder: An open label clinical trial pilot study compared with historical controls-Reference-Cited by-同舟云学术

Armodafinil to reduce the sleepiness related side‐effects of sleep restriction therapy being used to treat insomnia disorder: An open label clinical trial pilot study compared with historical controls

Published:2022-08-24 Issue:1 Volume:32 Page:
ISSN:0962-1105
Container-title:Journal of Sleep Research
language:en
Short-container-title:Journal of Sleep Research

Author:

Judge Daniel J.¹²³,Miller Christopher B.¹⁴^ORCID,Bartlett Delwyn J.¹⁵,Jomaa Ibrahim¹⁵,Wong Keith K. W.¹²⁵,Saini Bandana¹⁵,Semsarian Caitlin R.¹⁵^ORCID,Espie Colin A.⁶^ORCID,Kyle Simon D.⁶,Grunstein Ron R.¹²⁵,Yee Brendon J.¹²⁵,Marshall Nathaniel S.¹⁵^ORCID

Affiliation:

1. NeuroSleep and Woolcock Institute of Medical Research University of Sydney, Sydney New South Wales Australia

2. Department of Respiratory and Sleep Medicine, RPAH Sydney Local Health District Sydney New South Wales Australia

3. Department of Respiratory and Sleep Medicine Cairns Hospital Queensland Australia

4. Big Health Ltd London UK

5. Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia

6. Nuffield Department of Clinical Neurosciences and Sleep & Circadian Neuroscience Institute University of Oxford Oxford UK

Funder

National Health and Medical Research Council

Sydney Medical School

Publisher

Wiley

Subject

Behavioral Neuroscience,Cognitive Neuroscience,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jsr.13699

Reference46 articles.

1. Diagnostic and Statistical Manual of Mental Disorders

2. Sleep health New South Wales: chronic sleep restriction and daytime sleepiness

3. Insomnia

4. The Consensus Sleep Diary: Standardizing Prospective Sleep Self-Monitoring

5. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial